» Articles » PMID: 18299406

Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing

Overview
Specialty Pharmacology
Date 2008 Feb 27
PMID 18299406
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Oritavancin, a semisynthetic lipoglycopeptide with activity against gram-positive bacteria, has multiple mechanisms of action, including the inhibition of cell wall synthesis and the perturbation of the membrane potential. Approved guidelines for broth microdilution MIC assays with dalbavancin, another lipoglycopeptide, require inclusion of 0.002% polysorbate 80. To investigate the potential impact of polysorbate 80 on oritavancin susceptibility assays, we quantified the recovery of [(14)C]oritavancin from susceptibility assay plates with and without polysorbate 80 and examined the effect of the presence of polysorbate 80 on the oritavancin MICs for 301 clinical isolates from the genera Staphylococcus, Enterococcus, and Streptococcus. In the absence of polysorbate 80, [(14)C]oritavancin was rapidly lost from solution in susceptibility assay test plates: 9% of the input drug was recovered in broth at 1 h when [(14)C]oritavancin was tested at 1 mug/ml. Furthermore, proportionately greater losses were observed at lower oritavancin concentrations, suggesting saturable binding of oritavancin to surfaces. The inclusion of 0.002% polysorbate 80 or 2% lysed horse blood permitted the recovery of 80 to 100% [(14)C]oritavancin at 24 h for all drug concentrations tested. Concordantly, oritavancin MIC(90)s for streptococcal isolates, as determined in medium containing 2% lysed horse blood, were identical with and without polysorbate 80. In stark contrast, polysorbate 80 reduced the oritavancin MIC(90)s by 16- to 32-fold for clinical isolates of enterococci and staphylococci, which are typically cultured without blood. The results presented here provide evidence that the MIC data for oritavancin in the current literature significantly underestimate the potency of oritavancin in vitro. Moreover, the combination of data from MIC and [(14)C]oritavancin recovery studies supports the revision of the oritavancin broth microdilution method to include polysorbate 80 throughout the assay.

Citing Articles

Predominance of extensively-drug resistant Acinetobacter baumannii carrying bla OXA-23 in Jordanian patients admitted to the intensive care units.

Ababneh Q, Aldaken N, Jaradat Z, Al-Rousan E, Inaya Z, Alsaleh D PLoS One. 2025; 20(2):e0317798.

PMID: 40014590 PMC: 11867332. DOI: 10.1371/journal.pone.0317798.


Vancomycin-Teixobactin Conjugates.

Padilla M, Nowick J J Am Chem Soc. 2025; 147(8):6343-6348.

PMID: 39951395 PMC: 11869278. DOI: 10.1021/jacs.4c17175.


Potent Analogues of Clovibactin from Commercially Available Amino Acid Building Blocks.

Brunicardi J, Small J, Padilla M, Carrera Plancarte J, Nowick J J Org Chem. 2025; 90(5):2132-2136.

PMID: 39865672 PMC: 11812013. DOI: 10.1021/acs.joc.4c02828.


Altering glycopeptide antibiotic biosynthesis through mutasynthesis allows incorporation of fluorinated phenylglycine residues.

Voitsekhovskaia I, Ho Y, Klatt C, Muller A, Machell D, Tan Y RSC Chem Biol. 2024; .

PMID: 39247680 PMC: 11376024. DOI: 10.1039/d4cb00140k.


Investigation of Isobactin Analogues of Teixobactin.

Jones C, Lai G, Padilla M, Nowick J ACS Med Chem Lett. 2024; 15(7):1136-1142.

PMID: 39015269 PMC: 11247654. DOI: 10.1021/acsmedchemlett.4c00215.


References
1.
Kenny M, Brackman M . Comparison of agar dilution, tube dilution, and broth microdilution susceptibility tests for determination of ramoplanin MICs. J Clin Microbiol. 1994; 32(5):1364-5. PMC: 263704. DOI: 10.1128/jcm.32.5.1364-1365.1994. View

2.
Patel R, Rouse M, Piper K, Cockerill 3rd F, Steckelberg J . In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 1998; 30(2):89-92. DOI: 10.1016/s0732-8893(97)00207-1. View

3.
Jones R, Knapp C, Dowzicky M . Influence of polysorbate-80 when determining the tigecycline MIC by the reference method. Diagn Microbiol Infect Dis. 2007; 58(1):145-6. DOI: 10.1016/j.diagmicrobio.2006.11.019. View

4.
Barry A, Pfaller M, Fuchs P . Ramoplanin susceptibility testing criteria. J Clin Microbiol. 1993; 31(7):1932-5. PMC: 265664. DOI: 10.1128/jcm.31.7.1932-1935.1993. View

5.
Jones R, Stilwell M, Sader H, Fritsche T, Goldstein B . Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn Microbiol Infect Dis. 2006; 54(2):149-53. DOI: 10.1016/j.diagmicrobio.2005.08.015. View